ANRS IPERGAY Trial: Prophylaxis in men at risk of HIV
March 14, 2023
2015
ANRS IPERGAY TRIAL
On-demand preexposure prophylaxis in men at high risk for HIV-1 infection
Multicenter randomized, placebo controlled trial
Objective: To assess if on-demand pre-exposure prophylaxis around the time of sex reduce the transmission of HIV Among men who have sex with men and are at high risk for HIV transmission
400
Men, age ≥18, HIV-1 & 2 negative having anal sex with ≥2 partners in prior 6 months without consistent condom use were randomized to:
emtricitabine-
Matched
tenofovir
prophylaxis
VS
placebo
(n=201)
(n=199)
0.91
PRIMARY OUTCOME
HIV-1 infection
(per 100 person-years) RR 86%; 95% CI 40-98%; P=0.002
153
SECONDARY OUTCOME
6.60
Monthly pills taken
(median)
15
P=0.57
Post-exposure prophyaxis
31
during the study (N)
25
P=0.37
Conclusion: The use of TDF-FTC before and after sexual activity provided protection against HIV-1 infection in men who have sex with men. The treatment was associated with increased rates of gastrointestinal and renal adverse events.
Molina JM, et al. | NEJM, 2015; 373:2237-2246
